Q-omics provides the consensus-scored CCDC92 profile across patient tissues and cancer cell-line models. CCDC92 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CCDC92 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CCDC92 protein abundance shows 27,021 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where CCDC92 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC92 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC92 survival associations across molecular data types. CCDC92 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC92 RNA expression–survival associations across cancer types. High CCDC92 expression shows unfavorable associations in MESO and LGG, but favorable associations in SCLC, BRCA, UCEC and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CCDC92 RNA expression.
This table summarizes CCDC92 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC92. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC92 shows lower tumor expression in KICH, LUAD and UCEC and higher tumor expression in HNSC, LIHC and KIRC. The HNSC box plot shows higher CCDC92 RNA expression in tumor versus normal tissue (log2 FC = +0.943, t-test p < 0.001).
This table shows molecular features associated with CCDC92 in patient tissues and cancer cell lines. In patient samples, CCDC92 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC92 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
